<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602704</url>
  </required_header>
  <id_info>
    <org_study_id>HUHRD-SPE-15-05</org_study_id>
    <secondary_id>WI205578</secondary_id>
    <nct_id>NCT02602704</nct_id>
  </id_info>
  <brief_title>Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients</brief_title>
  <official_title>Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanyang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The purpose of this study is to study the effectiveness of bazedoxifene in preventing
           loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in
           postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.

        -  This is a randomized, controlled, open-label extension study for 48 or 56 weeks. At
           study entry, all patients will receive elemental calcium (1200 mg daily) and vitamin D
           (800 IU daily) and will be randomized by blocks of two to receive either bazedoxifene
           (20 mg/day) or none.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2015</start_date>
  <completion_date type="Anticipated">November 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Trabecular Bone Score (TBS)</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of the thoracic and lumbar vertebrae for deformities by visual inspection</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>confirmed through the thoracic spine X-ray and the lumbar spine X-ray. Check item: the location, the date of occurrence and the severity of fracture (mild, moderate, severe, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of any fractures including nonvertebral fractures</measure>
    <time_frame>Baseline, 24 weeks and 48 weeks</time_frame>
    <description>Measured by the questionnaire for fracture. Check item: the location and the date of occurrence of fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-terminal telopeptide (CTX)</measure>
    <time_frame>Baseline, 24 weeks and 48 weeks</time_frame>
    <description>Serum C-terminal telopeptide (CTX) in ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum bone specific alkaline phosphatase</measure>
    <time_frame>Baseline, 24 weeks and 48 weeks</time_frame>
    <description>Serum bone specific alkaline phosphatase in µg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum osteocalcin</measure>
    <time_frame>Baseline, 24 weeks and 48 weeks</time_frame>
    <description>Serum osteocalcin in ng/ml.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Bazedoxifene &amp; Calcium/Vit D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enrollment: 57
Drug: Bazedoxifene 20 mg/day (Viviant)
Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium/Vit D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enrollment: 57
Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bazedoxifene</intervention_name>
    <description>Bazedoxifene 20mg/day (Viviant) for 48 weeks</description>
    <arm_group_label>Bazedoxifene &amp; Calcium/Vit D</arm_group_label>
    <other_name>Viviant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium/Vit D</intervention_name>
    <description>Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks</description>
    <arm_group_label>Bazedoxifene &amp; Calcium/Vit D</arm_group_label>
    <arm_group_label>Calcium/Vit D</arm_group_label>
    <other_name>Hardcal Chewable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female RA patients ≥ 45 years old with self-reported postmenopausal for ≥12 months or
             prior hysterectomy with bilateral oophorectomy. Female patients ≥ 55 years old who had
             prior hysterectomy without oophorectomy or with unilateral oophorectomy.

          -  Having been receiving low to moderate dose of glucocorticoids (prednisone ≤7.5 mg/day
             or equivalent) for ≥3 months prior to entry. (When taking glucocorticoids PRN,
             prednisone ≥1mg/day in average.)

          -  Patients expected to be on glucocorticoid treatment for 3 months after entry.

          -  Patients with an osteopenic mean lumbar spine (LS; L1-L4) or femoral neck bone mineral
             density (BMD; -1 &lt; T-score &lt; -2.5)

          -  Patients who provide a written consent of participating in this study.

        Exclusion Criteria:

          -  Patients with condition that may interfere with the evaluation of spinal or hip
             osteoporosis by DXA such as two or more vertebral (L1-L4) fractures or other vertebral
             deformity

          -  Patients with hypercoagulability risk factors or a history of deep vein thrombosis and
             pulmonary embolism

          -  History of allergic reactions or intolerance to bazedoxifene or other SERM

          -  Patients receiving bisphosphonates, parathyroid hormone, SERMs, or anticonvulsants
             therapies within 6 months prior to entry

          -  Patients with known bone disorders such as osteomalacia, renal osteodystrophy and
             hyperparathyroidism

          -  Patients with undiagnosed uterine bleeding

          -  Patients with severe renal impairment or creatinine clearance &lt;30ml/min
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Kyoung Sung, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University Hospital for Rheumatic Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanyang University</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hanyang University</investigator_affiliation>
    <investigator_full_name>Yoon-Kyoung Sung</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Bazedoxifene</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

